Please use this identifier to cite or link to this item: doi:10.22028/D291-35470
Title: Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity
Author(s): Koch, Elias A. T.
Petzold, Anne
Wessely, Anja
Dippel, Edgar
Gesierich, Anja
Gutzmer, Ralf
Hassel, Jessica C.
Haferkamp, Sebastian
Kähler, Katharina C.
Knorr, Harald
Kreuzberg, Nicole
Leiter, Ulrike
Loquai, Carmen
Meier, Friedegund
Meissner, Markus
Mohr, Peter
Pföhler, Claudia
Rahimi, Farnaz
Schadendorf, Dirk
Schell, Beatrice
Schlaak, Max
Terheyden, Patrick
Thoms, Kai-Martin
Schuler-Thurner, Beatrice
Ugurel, Selma
Ulrich, Jens
Utikal, Jochen
Weichenthal, Michael
Ziller, Fabian
Berking, Carola
Heppt, Markus V.
Language: English
Title: Cancers
Volume: 14
Issue: 3
Publisher/Platform: MDPI
Year of Publication: 2022
Free key words: uveal melanoma
immune checkpoint blockade
treatment resistance
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: Re-induction with immune checkpoint blockade (ICB) needs to be considered in many patients with uveal melanoma (UM) due to limited systemic treatment options. Here, we provide hitherto the first analysis of ICB re-induction in UM. A total of 177 patients with metastatic UM treated with ICB were included from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of ICB re-induction, two cohorts were compared: patients who received at least one ICB re-induction (cohort A, n = 52) versus those who received only one treatment line of ICB (cohort B, n = 125). In cohort A, a transient benefit of overall survival (OS) was observed at 6 and 12 months after the treatment start of ICB. There was no significant difference in OS between both groups (p = 0.1) with a median OS of 16.2 months (cohort A, 95% CI: 11.1–23.8) versus 9.4 months (cohort B, 95% CI: 6.1–14.9). Patients receiving re-induction of ICB (cohort A) had similar response rates compared to those receiving ICB once. Re-induction of ICB may yield a clinical benefit for a small subgroup of patients even after resistance or development of toxicities.
DOI of the first publication: 10.3390/cancers14030518
Link to this record: urn:nbn:de:bsz:291--ds-354700
ISSN: 2072-6694
Date of registration: 17-Feb-2022
Faculty: M - Medizinische Fakultät
Department: M - Dermatologie
Professorship: M - Keiner Professur zugeordnet
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Files for this record:
File Description SizeFormat 
cancers-14-00518-v2.pdf712,15 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons